Dosage adjustment of quinolone antibiotics and angiotensin-converting enzyme inhibitors in patients with renal dysfunction

Hisakazu Ohtani, Y. Kinoshita, Y. Nagasaki, H. Sata, A. Miki, M. Tsujimoto, Y. Sawada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this study was to verify an approach for calculating pharmacokinetic parameters suitable for adjusting dosage regimens in patients with renal dysfunction. We carried out a retrospective analysis of the pharmacokinetic profiles of 12 new quinolone antibiotics and 11 angiotensin-converting enzyme inhibitors (ACEIs) in patients with normal and impaired renal function to obtain the renal excretion ratio (Rrenal) of each drug. We demonstrated that the pharmacokinetics of each drug in a patient with renal dysfunction can be adequately estimated using the Rrenal value of each drug together with the creatinine clearance as an index of the individual's renal function. Using the Rrenal value obtained, we could successfully simulate pharmacokinetic profiles of the drugs in publications other than that used to obtain the Rrenal values. On the other hand, age-related changes in the pharmacokinetics of new quinolone antibiotics are not always adequately predicted using the Rrenal value compared to using creatinine clearance alone as an index, and the reasons for this are not fully understood. These results demonstrate that dosage regimens of quinolone antibiotics and ACEIs in patients with renal dysfunction can be adequately optimized using the Rrenal value for each drug using the present approach.

Original languageEnglish
Pages (from-to)428-437
Number of pages10
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume44
Issue number9
Publication statusPublished - 2006 Sep
Externally publishedYes

Fingerprint

Pharmacokinetics
Quinolones
Angiotensin-Converting Enzyme Inhibitors
Anti-Bacterial Agents
Kidney
Pharmaceutical Preparations
Creatinine
Publications

Keywords

  • Creatinine clearance
  • Elderly
  • Pharmacokinetics
  • Renal failure

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Cite this

Dosage adjustment of quinolone antibiotics and angiotensin-converting enzyme inhibitors in patients with renal dysfunction. / Ohtani, Hisakazu; Kinoshita, Y.; Nagasaki, Y.; Sata, H.; Miki, A.; Tsujimoto, M.; Sawada, Y.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 44, No. 9, 09.2006, p. 428-437.

Research output: Contribution to journalArticle

@article{c2ba705d9dd8426c8a3d8fbde0ae1b6b,
title = "Dosage adjustment of quinolone antibiotics and angiotensin-converting enzyme inhibitors in patients with renal dysfunction",
abstract = "The aim of this study was to verify an approach for calculating pharmacokinetic parameters suitable for adjusting dosage regimens in patients with renal dysfunction. We carried out a retrospective analysis of the pharmacokinetic profiles of 12 new quinolone antibiotics and 11 angiotensin-converting enzyme inhibitors (ACEIs) in patients with normal and impaired renal function to obtain the renal excretion ratio (Rrenal) of each drug. We demonstrated that the pharmacokinetics of each drug in a patient with renal dysfunction can be adequately estimated using the Rrenal value of each drug together with the creatinine clearance as an index of the individual's renal function. Using the Rrenal value obtained, we could successfully simulate pharmacokinetic profiles of the drugs in publications other than that used to obtain the Rrenal values. On the other hand, age-related changes in the pharmacokinetics of new quinolone antibiotics are not always adequately predicted using the Rrenal value compared to using creatinine clearance alone as an index, and the reasons for this are not fully understood. These results demonstrate that dosage regimens of quinolone antibiotics and ACEIs in patients with renal dysfunction can be adequately optimized using the Rrenal value for each drug using the present approach.",
keywords = "Creatinine clearance, Elderly, Pharmacokinetics, Renal failure",
author = "Hisakazu Ohtani and Y. Kinoshita and Y. Nagasaki and H. Sata and A. Miki and M. Tsujimoto and Y. Sawada",
year = "2006",
month = "9",
language = "English",
volume = "44",
pages = "428--437",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "9",

}

TY - JOUR

T1 - Dosage adjustment of quinolone antibiotics and angiotensin-converting enzyme inhibitors in patients with renal dysfunction

AU - Ohtani, Hisakazu

AU - Kinoshita, Y.

AU - Nagasaki, Y.

AU - Sata, H.

AU - Miki, A.

AU - Tsujimoto, M.

AU - Sawada, Y.

PY - 2006/9

Y1 - 2006/9

N2 - The aim of this study was to verify an approach for calculating pharmacokinetic parameters suitable for adjusting dosage regimens in patients with renal dysfunction. We carried out a retrospective analysis of the pharmacokinetic profiles of 12 new quinolone antibiotics and 11 angiotensin-converting enzyme inhibitors (ACEIs) in patients with normal and impaired renal function to obtain the renal excretion ratio (Rrenal) of each drug. We demonstrated that the pharmacokinetics of each drug in a patient with renal dysfunction can be adequately estimated using the Rrenal value of each drug together with the creatinine clearance as an index of the individual's renal function. Using the Rrenal value obtained, we could successfully simulate pharmacokinetic profiles of the drugs in publications other than that used to obtain the Rrenal values. On the other hand, age-related changes in the pharmacokinetics of new quinolone antibiotics are not always adequately predicted using the Rrenal value compared to using creatinine clearance alone as an index, and the reasons for this are not fully understood. These results demonstrate that dosage regimens of quinolone antibiotics and ACEIs in patients with renal dysfunction can be adequately optimized using the Rrenal value for each drug using the present approach.

AB - The aim of this study was to verify an approach for calculating pharmacokinetic parameters suitable for adjusting dosage regimens in patients with renal dysfunction. We carried out a retrospective analysis of the pharmacokinetic profiles of 12 new quinolone antibiotics and 11 angiotensin-converting enzyme inhibitors (ACEIs) in patients with normal and impaired renal function to obtain the renal excretion ratio (Rrenal) of each drug. We demonstrated that the pharmacokinetics of each drug in a patient with renal dysfunction can be adequately estimated using the Rrenal value of each drug together with the creatinine clearance as an index of the individual's renal function. Using the Rrenal value obtained, we could successfully simulate pharmacokinetic profiles of the drugs in publications other than that used to obtain the Rrenal values. On the other hand, age-related changes in the pharmacokinetics of new quinolone antibiotics are not always adequately predicted using the Rrenal value compared to using creatinine clearance alone as an index, and the reasons for this are not fully understood. These results demonstrate that dosage regimens of quinolone antibiotics and ACEIs in patients with renal dysfunction can be adequately optimized using the Rrenal value for each drug using the present approach.

KW - Creatinine clearance

KW - Elderly

KW - Pharmacokinetics

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=33750702230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750702230&partnerID=8YFLogxK

M3 - Article

C2 - 16995331

AN - SCOPUS:33750702230

VL - 44

SP - 428

EP - 437

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 9

ER -